Epstein-Barr virus nuclear antigen 1 peptide-HLA complex (EBNA1-pHLA)

Epstein-Barr virus nuclear antigen 1 (EBNA1) peptide-HLA complexes are essential immunological targets for treating EBV-associated malignancies and certain autoimmune conditions. EBNA1 is a multifunctional viral protein required for the replication and maintenance of the EBV episome, and it is uniquely expressed in all forms of EBV latency, making it a consistent marker for infected cells (UniProt: P03211). These complexes form when EBNA1 is processed by the host cell and its constituent peptides are loaded onto Human Leukocyte Antigen (HLA) Class I or Class II molecules for presentation on the cell surface. Recognition of these complexes by CD8+ or CD4+ T-cell receptors (TCRs) triggers a targeted immune response against EBV-positive cells, such as those found in nasopharyngeal carcinoma and Hodgkin lymphoma (PubMed: 23043071). In therapeutic development, these complexes are targeted by adoptive T-cell therapies, TCR-engineered T cells, and TCR-mimetic antibodies designed to bypass the virus's natural immune evasion mechanisms (PubMed: 31534004). However, a significant challenge is the potential for molecular mimicry, as EBNA1-specific immune responses have been shown to cross-react with host proteins like GlialCAM, contributing to the pathogenesis of multiple sclerosis (Nature 2022, 603:132-138).

Other names

EBNA1-MHC complexEBNA1-pMHCEBV EBNA1 peptide-HLA complexEBNA1-derived peptide-HLA complexEBNA1-HLA class I complexEBNA1-HLA class II complex

Targeting of EBV-infected cells via T-cell receptor (TCR) recognition of EBNA1-derived peptides presented on HLA molecules, leading to cytotoxic T-lymphocyte (CTL) mediated lysis, cytokine release, and elimination of the target cell (PubMed: 31534004).